Sunitinib dose-escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib clinical efficacy, eventually patients develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Adelaiye, Remi, Ciamporcero, Eric, Miles, Kiersten Marie, Sotomayor, Paula, Bard, Jonathan, Tsompana, Maria, Conroy, Dylan, Shen, Li, Ramakrishnan, Swathi, Ku, Sheng-Yu, Orillion, Ashley, Prey, Joshua, Fetterly, Gerald, Buck, Michael, Chintala, Sreenivasulu, Bjarnason, Georg A., Pili, Roberto
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326587/
https://ncbi.nlm.nih.gov/pubmed/25519701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0208
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars